Familial Adenomatous Polyposis (FAP) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Familial adenomatous polyposis (FAP) is an inherited condition that primarily affects the gastrointestinal tract. This condition causes hundreds or thousands of polyps to form inside the colon and rectum. This condition is also known as hereditary polyposis of the colorectum, Gardner's syndrome, and familial polyposis. Nearly 100% progression to colorectal cancer (CRC) by the age of 35–40 yr and a heightened risk of various other malignancies. Familial adenomatous polyposis (FAP) is a highly penetrant autosomal-dominant disorder caused by a germline mutation in the adenomatous polyposis coli (APC) gene chromosome 5q21. Over 700 different disease-causing APC mutations have been reported to date. However, the most common germline mutation involves the introduction of a premature stop codon, either by a nonsense mutation (30%), frameshift mutation (68%), or large deletion (2%), leading to truncation of the protein product in the C-terminal region.
The birth frequency of Familial
adenomatous polyposis (FAP) in the USA and European populations is estimated at
roughly 1.5 in 15,000 to 1.89 in 18,000 live births, respectively. It is also
responsible for less than 1% of all CRC cases.
The competitive
landscape of Familial Adenomatous Polyposis (FAP) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Familial
Adenomatous Polyposis (FAP) across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Familial
Adenomatous Polyposis (FAP) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 REC-4881 Recursion Phase 2
2 Encapsulated Rapamycin (eRapa) Emtora Biosciences Phase
2
3 Eicosapentaenoic acid free fatty acid (EPA-FFA) S.L.A. Pharma AG Phase 3
4 Eflornithine Cancer
Prevention Pharmaceuticals, Inc. Phase
3
5 celecoxib Pfizer Phase 1
Comments
Post a Comment